{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:43:47Z","timestamp":1787013827161,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":801,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1111\/ajt.15922","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T01:45:31Z","timestamp":1587087931000},"page":"2581-2588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0456-8635","authenticated-orcid":false,"given":"Stanley C.","family":"Jordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Kucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Bagger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Ulrich","family":"Hockey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2121-9397","authenticated-orcid":false,"given":"Noriko","family":"Ammerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1111\/ajt.15922_bib1","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial","volume":"15","author":"Jordan","year":"2004","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"10.1111\/ajt.15922_bib2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/TP.0b013e3182802f88","article-title":"Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab","volume":"95","author":"Vo","year":"2013","journal-title":"Transplantation."},{"issue":"4","key":"10.1111\/ajt.15922_bib3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ctr.12335","article-title":"Desensitization in kidney transplantation: review and future perspectives","volume":"28","author":"Abu Jawdeh","year":"2014","journal-title":"Clin Transplant."},{"issue":"13","key":"10.1111\/ajt.15922_bib4","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1302506","article-title":"Complement-binding anti-HLA antibodies and kidney-allograft survival","volume":"369","author":"Loupy","year":"2013","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1111\/ajt.15922_bib5","doi-asserted-by":"crossref","first-page":"e1002572","DOI":"10.1371\/journal.pmed.1002572","article-title":"Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: a systematic review and meta-analysis","volume":"15","author":"Bouquegneau","year":"2018","journal-title":"PLoS Med."},{"issue":"S1","key":"10.1111\/ajt.15922_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2009.03955.x","article-title":"Mechanisms of action of immune globulin","volume":"157","author":"Fernandez-Cruz","year":"2009","journal-title":"Clin Exp Immunol."},{"issue":"21","key":"10.1111\/ajt.15922_bib7","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1111\/ajt.15922_bib8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/imr.12331","article-title":"The multiple facets of FcRn in immunity","volume":"268","author":"Stapleton","year":"2015","journal-title":"Immunol Rev."},{"issue":"3","key":"10.1111\/ajt.15922_bib9","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.transproceed.2015.11.028","article-title":"Complement inhibition for prevention and treatment of antibody-mediated rejection in renal allograft recipients","volume":"48","author":"Jordan","year":"2016","journal-title":"Transplant Proc."},{"issue":"11","key":"10.1111\/ajt.15922_bib10","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transplant."},{"issue":"2","key":"10.1111\/ajt.15922_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/TP.0000000000000592","article-title":"A phase I\/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation."},{"issue":"3","key":"10.1111\/ajt.15922_bib12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.trre.2013.04.002","article-title":"Eculizumab in renal transplantation","volume":"27","author":"Legendre","year":"2013","journal-title":"Transplant Rev."},{"issue":"2","key":"10.1111\/ajt.15922_bib13","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1681\/ASN.2017050589","article-title":"Complement-activating anti-HLA antibodies in kidney transplantation: allograft gene expression profiling and response to treatment","volume":"29","author":"Lefaucheur","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"13","key":"10.1111\/ajt.15922_bib14","first-page":"3433","article-title":"Generation and characterization of LFG316, a fully-human anti-C5 antibody for the treatment of age-related macular degeneration","volume":"55","author":"Roguska","year":"2014","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"7","key":"10.1111\/ajt.15922_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20071693","article-title":"Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules","volume":"20","author":"Nebbioso","year":"2019","journal-title":"Int J Mol Sci."},{"key":"10.1111\/ajt.15922_bib16","unstructured":"NCT01624636. Safety and tolerability of intravenous LFG316 in wet age-related macular degeneration (AMD). April 25, 2016. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01624636. Accessed September 6, 2019."},{"key":"10.1111\/ajt.15922_bib17","unstructured":"NCT01527500. Intravitreal LFG316 in patients with age-related macular degeneration (AMD). April 9, 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01527500. Accessed September 6, 2019."},{"key":"10.1111\/ajt.15922_bib18","unstructured":"NCT02534909. Proof of concept study to assess the efficacy, safety and pharmacokinetics of LFG316 in patients with paroxysmal nocturnal hemoglobinuria. July 19, 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02534909. Accessed September 6, 2019."},{"issue":"7","key":"10.1111\/ajt.15922_bib19","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.170.7.3528","article-title":"The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs","volume":"170","author":"Roopenian","year":"2003","journal-title":"J Immunol."},{"issue":"45","key":"10.1111\/ajt.15922_bib20","doi-asserted-by":"crossref","first-page":"14649","DOI":"10.1021\/bi00045a005","article-title":"Analysis of the pH dependence of the neonatal Fc receptor\/immunoglobulin G interaction using antibody and receptor variants","volume":"34","author":"Raghavan","year":"1995","journal-title":"Biochemistry."},{"issue":"32","key":"10.1111\/ajt.15922_bib21","doi-asserted-by":"crossref","first-page":"9698","DOI":"10.1021\/bi000749m","article-title":"Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,)","volume":"39","author":"West","year":"2000","journal-title":"Biochemistry."},{"issue":"8","key":"10.1111\/ajt.15922_bib22","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1073\/pnas.0810796106","article-title":"Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice","volume":"106","author":"Montoyo","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"issue":"12","key":"10.1111\/ajt.15922_bib23","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J Clin Invest."},{"issue":"2","key":"10.1111\/ajt.15922_bib24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1529-8027.2011.00328.x","article-title":"An open label clinical trial of complement inhibition in multifocal motor neuropathy","volume":"16","author":"Fitzpatrick","year":"2011","journal-title":"J Peripher Nerv Syst."},{"issue":"2","key":"10.1111\/ajt.15922_bib25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/TP.0000000000000958","article-title":"One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial","volume":"100","author":"Sautenet","year":"2016","journal-title":"Transplantation."},{"issue":"2","key":"10.1111\/ajt.15922_bib26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.trre.2017.01.002","article-title":"A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection","volume":"31","author":"Macklin","year":"2017","journal-title":"Transplant Rev."},{"issue":"4","key":"10.1111\/ajt.15922_bib27","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/ajt.14520","article-title":"Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: a multicenter, prospective, randomized, double-blind clinical trial","volume":"18","author":"Moreso","year":"2018","journal-title":"Am J Transplant."},{"issue":"414","key":"10.1111\/ajt.15922_bib28","doi-asserted-by":"crossref","first-page":"eaan1208","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med."},{"issue":"1","key":"10.1111\/ajt.15922_bib29","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1038\/s41598-018-23481-5","article-title":"In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor","volume":"8","author":"Seijsing","year":"2018","journal-title":"Sci Rep."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.15922","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15922","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajt.15922","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522225763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522225763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:29:49Z","timestamp":1761629389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522225763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1600613522225763"],"URL":"https:\/\/doi.org\/10.1111\/ajt.15922","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.15922","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}